Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

This study reports that the compound CS-891 can inhibit 5alpha-reductase activity in the dermal papillae of human hair follicles, suggesting potential for treating androgenetic alopecia.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

In this study, a herbal preparation inhibited the conversion of testosterone to DHT and its binding on hair roots in vitro, suggesting potential as an alternative treatment for androgenic alopecia without the safety concerns associated with finasteride.

This narrative review discusses adverse effects associated with 5-ARI treatments for male-pattern baldness and benign prostate hyperplasia, including sexual health, neurological, endocrine, metabolic, and cardiovascular impacts, and emphasizes careful prescription assessment.

This study found that cyproterone acetate significantly reduced both serum 3α-AdiolG levels and hirsutism scores in women with idiopathic hirsutism, PCOS, or 21-hydroxylase deficiency, suggesting its effectiveness in treating excessive hair growth.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

This review provides an overview of clinically approved small molecule drugs targeting androgen receptors and discusses therapeutic applications, without presenting new experimental results.

This mini review explores the potential of herbal testosterone 5α-reductase inhibitors for treating androgenetic alopecia, suggesting they might offer fewer side effects and better tolerability than traditional treatments like finasteride and minoxidil.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This study identified a novel class of nonsteroidal ligands that can mimic the effects of dihydrotestosterone on androgen receptors, suggesting potential therapeutic applications in male fertility and hormone replacement therapy.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

This study found that finasteride decreased plasma dihydrotestosterone levels and altered steroid metabolism, similar to the profile of male pseudohermaphrodites with inherited 5a-reductase deficiency.

This study found that finasteride administered for 28 days had no significant effect on adrenal steroidogenesis in healthy men, aside from inhibiting androstenedione metabolism.

This review discusses various anti-androgen treatments for hirsutism, including androgen receptor blockers and inhibitors, and emphasizes the role of diagnosis in selecting the most appropriate therapy, but reports no new clinical results.